SCHEDULE 13G: Weber Capital Management Discloses 5.77% Passive Stake in Harvard Bioscience

Weber Capital Management, LLC has reported a passive beneficial ownership of 5.77% in Harvard Bioscience, Inc., holding over 2.5 million shares as of December 31, 2024.

Summary

• Weber Capital Management, LLC, an investment adviser based in San Francisco, CA, has filed a Schedule 13G with the SEC.
• The filing indicates that Weber Capital Management beneficially owns 2,516,930 shares of Harvard Bioscience, Inc. Common Stock.
• This ownership represents 5.77% of the outstanding class of securities.
• The shares are held with shared voting power and shared dispositive power.
• The filing date for this statement was February 10, 2025, reflecting ownership as of December 31, 2024.
• Weber Capital Management certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Harvard Bioscience, Inc.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates institutional interest and confidence in Harvard Bioscience, Inc., without any negative implications from the filing itself.

Positives

• The disclosure of a significant stake by an institutional investor like Weber Capital Management can signal confidence in Harvard Bioscience's long-term prospects.
• A 5.77% ownership by a recognized investment adviser may attract further institutional interest in the company.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment strategy by Weber Capital Management.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Harvard Bioscience, Inc.'s future performance or outlook. It solely reports a beneficial ownership stake.

Management Comments

• Colin Hillberg, Manager of Weber Capital Management, LLC, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

Harvard Bioscience, Inc. operates in the life sciences tools and services industry, providing products to researchers worldwide. The disclosure of a significant passive stake by an investment adviser is a common occurrence in the public markets, reflecting institutional portfolio allocation decisions within the sector.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a new large passive shareholder, though without immediate control implications.

Key Dates

Keywords

Harvard Bioscience, Weber Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Adviser, Passive Investment